<DOC>
	<DOCNO>NCT00990821</DOCNO>
	<brief_summary>This 5-part study evaluate safety , tolerability , pharmacokinetics two formulation MK-0517 ( without polysorbate 80 ) aprepitant healthy adult . Parts I IV study examine different dos MK-0517 well two different formulation MK-0517 ( without polysorbate 80 ) . Part V study compare single dose intravenous non-PS80 MK-0517 oral 125-mg capsule aprepitant . The primary hypothesis Part V study single intravenous dose 100-mg 115-mg MK-0517 area plasma-time curve ( AUC ) equivalent 125-mg oral aprepitant capsule young healthy participant .</brief_summary>
	<brief_title>A Study Investigate Safety Tolerability MK-0517 Healthy Subjects ( MK-0517-012 )</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Postoperative Nausea Vomiting</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Subject neither grossly overweight underweight his/her height body build Subject good health Subject nonsmoker Subject willing avoid excessive alcohol consumption duration study Subject willing avoid strenuous physical activity ( i.e . unaccustomed weight lifting , run , bicycle ) duration study Subject agree refrain consumption grapefruit ( grapefruit product ) study Subject history multiple and/or severe allergy drug food Subject donate blood take investigational drug another clinical trial within last 4 week Subject infection , include Human immunodeficiency virus ( HIV ) infection Subject regular user illicit drug Subject consume excessive amount alcohol Subject drink excessive amount coffee , tea , cola caffeinated beverage Subject currently use regular basis , prescription non prescription medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>